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The fish-eating cone snails do not 
mess around; they don’t have that 
luxury Their prey - often larger than 
the snails themselves, and considerably 
more mobile - cannot be allowed to 
wriggle free or attract the attention of 
other predators. So the cone snails hit 
fish with a cocktail of peptide toxins 
that have a succession of nasty effects. 
Some toxins open ion channels to 
immobilize the fish with a quick 
tetanic shock; others block channels at 
the neuromuscular junction to more 
permanently shut down any muscle 
action; still others block calcium 
channels to shut off all communication 
between nerves. The end result of 
this chemical carnage is not surprising. 
The fish becomes an easy meal. 
It is from this poisonous mixture 
that Neurex Corporation (Menlo 
Park, California) and Cognetix Inc. 
(Salt Lake City, Utah) think they can 
extract human pharmaceuticals. 
Simple beginnings 
Baldomero Olivera was trained in the 
well-funded laboratories of the 
California Institute of Technology 
and Stanford University. But when he 
returned to his home country, to take 
a position at the University of the 
Philippines, money and equipment 
became a problem. Molecular biology 
was out of the question. 
He turned to the genus Conus, the 
cone snails that shuffled around local 
coral reefs. He knew about them 
from his youth, and was familiar with 
the reports that one species, Conw 
geograplz~~, had killed humans. It 
seemed a reasonable proposition to 
study Conusgeograpr?~ to find what 
made it lethal. “We thought the 
venoms would be relatively simple,” 
he says. “We just thought we would 
categorize a couple of toxins.” 
The analysis soon became far 
more complex. The toxin had many 
different molecules in it, visible as 
separate chromatographic peaks. But 
was the complexity a red herring? 
“There were a lot of peaks, but a lot 
of them were inactive,” says Olivera. 
“We weren’t sure what to make of 
these inactive peaks.” 
The toxins, dubbed conotoxins, 
were small peptides of lo-30 amino 
acids. They paralyzed fish, so Olivera 
was testing them by looking for 
paralysis in mice after intravenous 
injection. When so many toxins tested 
negative he went back to studying 
DNA replication, eventually at the 
University of Utah (Salt Lake City, 
Utah). Everything changed when 
graduate student Craig Clark decided 
to inject the individual peptide toxins 
into the central nervous system of the 
test mice. Previously inactive toxins 
now caused the mice to jump, sleep, 
scratch, drag their hind legs, swing 
their heads or shake. Olivera had hit a 
neurological gold mine. 
Lucky for some 
Unfortunately the University of Utah 
was not ready for Olivera’s gold 
mine. They patented some of the 
earliest conotoxins, but not the initial 
o-conotoxins. “I did make some 
moves to get them patented but the 
University of Utah tech transfer 
office was in transition and disarray,” 
says Olivera. “We needed to get our 
stuff out and published, because we 
needed to renew our grants, so the 
o-conotoxins became part of the 
public domain.” 
George Miljanich of the 
University of Southern California 
wanted o-conotoxins for his work on 
neurotransmitter release. Unlike 
existing calcium channel blockers, 
such as the cardiac drugs nifedipine 
and nitrendipine, the co-conotoxins 
bound to the neuronal (N-type) not 
cardiac (L-type) calcium channels, 
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Figure 1 
The diner becomes dinner. (a) The fish-eating 
Conus snails use a proboscis that looks like a 
tasty worm to attract a fish. (b) Conus injects 
poison using a chitin harpoon launched from 
the proboscis, and then emerges from the 
gravel to engulf the paralyzed fish. 
thus preventing the calcium influx 
needed for neurotransmitter release. 
In 1988, Miljanich was recruited 
by a start-up called Neurex. The year- 
old company wanted to find drugs 
specific to subtypes of neurological ion 
channels and receptors. But Neurex 
had a long hard road ahead of it. It was 
hoping to identify receptors, clone 
them, and then find subtype-specific 
inhibitors. When Miljanich brought 
the a-conotoxins he skipped straight 
to the last step, and in the process he 
probably saved the company. 
Things moved slowly at first. 
“The concept of peptides that could 
become drugs was met with some 
degree of skepticism,” says 
Miljanich. “They were more keen on 
a small-molecule approach.” 
Fortunately the conotoxins already 
showed some properties more usually 
associated with small molecules than 
with peptides. All this is thanks to the 
snail’s hunting strategy. The snails use 
small peptides because they diffuse 
rapidly through a poisoned fish, but 
for Neurex that meant a simple solid- 
phase synthesis. And the snail had 
evolved rigid molecules that avoid 
dilution by binding only one type of 
receptor very tightly, so Neurex now 
had potent, specific drugs that were 
resistant to degradation. 
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lntrathecal snails for pain relief 
Based on binding affinities, Neurex’s 
lead o-conotoxin became the Conzcs 
mugus toxin variously known as 
MVIIA, SNX-111, or ziconotide. The 
drug now had to be matched with a 
disease. “Any disease that could be 
improved by controlling synaptic 
release was fair game for treating with 
conotoxins,” says Miljanich. The 
pattern of ziconotide binding to a 
specific part of the spinal cord 
suggested that the drug might be 
useful for pain. Ziconotide would not 
shut down the entire nervous system 
because P- and Q-type calcium 
channels were regulating synaptic 
release in other neurons. 
Animal models of pain gave 
promising results. With an assay in 
hand, Neurex tried to improve 
ziconotide. “We tried to do better 
than what fifty million years of 
evolution had given us, but SNX-111 
proved to be the superior 
compound,” says Miljanich. “After 
hundreds of analogs, we went back 
to the original compound.” 
In animals and then humans, 
ziconotide was proving to have 
several advantages over opiates such 
as morphine. In some patients 
ziconotide caused mental fogginess 
(as is seen with morphine), but it did 
not cause constipation or respiratory 
suppression, and unlike the opiates it 
was effective against neuropathic 
pain, which is the result of nerve 
rather than tissue injury. And there 
was no tolerance. “We never saw any 
signs of tolerance in animals or in 
patients,” says Miljanich. “The dose 
we give in the first week is equally 
effective a year later.” 
The reason is simple. “Ziconotide 
is an antagonist whereas morphine is 
an agonist of its receptor,” says 
Miljanich. “To subvert the actions of 
an agonist, the cell just has to 
inactivate or to stop producing the 
receptor - then you’ve got tolerance. 
To overcome an antagonist the cell 
would have to increase the amount of 
receptor and there’s a limit to that. 
There’s only so many calcium channels 
that a cell can jam into a membrane.” 
What exactly is being blocked is 
unclear, although Miljanich guesses 
that neurotransmitters such as 
glutamate and substance P are no 
longer released. Ziconotide’s method 
of action is clearer for its second 
application: blocking cell death in 
the brain after head trauma and 
stroke. It prevents the calcium 
influxes that both directly lead to 
apoptotic cell death, and that lead to 
excess glutamate release and so 
excitotoxic cell death. 
But clinical trials with head trauma 
victims showed that ziconotide was 
not without its problems. The trials 
were suspended when intravenous 
ziconotide depressed blood pressure: 
the drug had inhibited norepinephrine 
release by sympathetic nerves to the 
smooth muscles that maintain blood 
pressure. This problem is now 
managed in hospitals with fluids and 
counteractive drugs, and intravenous 
ziconotide is now in phase III trials. 
The solution for pain patients is 
to deliver ziconotide directly to the 
spine so that it never circulates 
through the rest of the body. Neurex 
has teamed up with Medtronic, Inc. 
(Minneapolis, Minnesota) to produce 
a pump system that delivers a 
constant flow to the spinal cord. 
The pump is the size of a hockey 
puck, and is implanted in the chest 
and refilled by syringe. Phase III 
trials for pain were completed earlier 
this year, and Neurex expects to file 
a new drug application in the next 
six months. 
Olivera finally gets some action 
The University of Utah had lost the 
o-conotoxins, but now they were 
paying more attention to Olivera. 
Unfortunately he just wouldn’t stop 
producing more, novel conotoxins. 
“We were beginning to eat up a 
significant portion of the University 
budget for patents,” he says. 
The solution was Cognetix. 
Formed in 1993, the company now 
has or has applied for patents 
covering over one hundred 
conotoxins. Cognetix isolates toxins 
based on their effects on ion channel 
activity, using both electrophysiology 
and fluorescent dyes that respond to 
differences in intracellular ion 
concentration. Toxin targets include 
nicotinic acetylcholine receptors 
(nAChR), calcium channels, 
N-methyl-D-aspartate receptors 
(NMDA-R), sodium channels, 
potassium channels and, recently, a 
serotonin receptor. 
The main disease targets, all pre- 
clinical, include Parkinson’s disease 
(using NMDA-R antagonists to 
indirectly increase dopamine release), 
urinary dysfunction in spinal-cord 
patients (using nAChR or NMDA-R 
antagonists to open the urinary 
sphincter), epilepsy (using NMDA-R 
antagonists to prevent over- 
excitation) and pain (various 
approaches). Cognetix hopes to start 
clinical trials for intractable epilepsy 
in 1999. The possible market 
includes the many epileptics (up to 
one third) who do not respond to 
existing drugs. 
Both Neurex and Cognetix are 
trying to replace conotoxins with 
orally available small molecules. 
Olivera sees this as a challenge that 
may take a new approach. “If one 
simply screens for competitors of 
toxin binding it may be difficult to 
obtain the same discrimination 
between receptor subtypes,” he says. 
If the companies cannot solve 
the rules of conotoxin binding and 
apply them to small molecules, there 
is always luck. It has already struck 
once in this story. Olivera focused on 
fish-eating rather than worm-eating 
snails because he hoped that toxins 
designed to hit certain vertebrates 
(fish) would also work on mice and 
humans. But ziconotide doesn’t kill 
humans precisely because it doesn’t 
fit this pattern. Mammals have 
evolved calcium channels at the 
neuromuscular junction that, unlike 
those in fish, are insensitive to 
ziconotide. As Miljanich says, “lucky 
for pain sufferers, and for Neurex.” 
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